Yet GSK is clearly healing from its multiple comorbidities — the worst of which was the (now largely resolved) legal overhang related to heartburn medicine Zantac. Chief executive Emma Walmsley also ...

GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

A new computational tool could help researchers identify promising drug combinations for treating cancer, according to a new ...

Scientists have developed retriever, a computational tool that extracts disease-specific drug response signatures to predict the best combinations for cancer treatment.

retriever generates disease-specific transcriptional drug response signatures by merging transcriptional signatures over time, concentration, and cell-type. These signatures can then be matched to ...

With the FDA quietly rolling back DEI initiatives under Trump’s latest executive order, experts warn that underrepresentation ...

GSK and the University of Oxford have joined hands to focus on the potential of cancer prevention through vaccination. The ...

“In addition to decreasing the inflammation by decreasing lesional staphylococcus aureus, the mupirocin treatment also lowered skin monocyte levels, which are important in driving cutaneous lupus,” ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.